文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

夏威夷COVID-19住院患者的保险覆盖、种族与民族及疫苗接种模式

COVID-19 Hospitalization in Hawai'i and Patterns of Insurance Coverage, Race and Ethnicity, and Vaccination.
PubMed 文献 · JAMA Netw Open · 2024-05-01
一句话结论在夏威夷住院COVID-19患者中,保险类型与ICU转入及院内死亡无关;接种至少1剂COVID-19疫苗者ICU转入(OR 0.40)和院内死亡(OR 0.42)均降低。

这项回顾性队列研究纳入2020年3月至2022年3月一家三级医疗中心1176例急性COVID-19住院患者,评估保险覆盖、种族与民族(使用分解数据)及疫苗接种与ICU转入和院内死亡的关系。调整年龄、BMI、性别、合并症及社区社会经济状况后,保险类型与ICU转入或院内死亡无关;分解种族与民族显示菲律宾裔患者院内死亡风险更高(OR 1.79)。接种至少1剂COVID-19疫苗者ICU转入(OR 0.40)和院内死亡(OR 0.42)均降低;作者认为疫苗接种仍是保护患者免于COVID-19死亡的关键工具。

要点

  • 调整年龄、BMI、性别、合并症及社区社会经济状况后,保险类型与ICU转入无关(Medicare vs 商业保险:OR 0.84;95%CI 0.43-1.64)。
  • 调整后保险类型与院内死亡无关(Medicare vs 商业保险:OR 0.85;95%CI 0.36-2.03)。
  • 分解种族与民族显示菲律宾裔患者院内死亡风险更高(OR 1.79;95%CI 1.04-3.03;P=.03)。
  • 接种至少1剂COVID-19疫苗者ICU转入降低(OR 0.40;95%CI 0.21-0.70;P=.002)、院内死亡降低(OR 0.42;95%CI 0.21-0.79;P=.01)。
  • Medicare保险患者较商业保险患者更可能接种至少1剂COVID-19疫苗(OR 1.85;95%CI 1.07-3.21;P=.03)。

适用人群与场景

  • 2020年3月至2022年3月在一家三级医疗中心住院的急性COVID-19患者,基于诊断代码或SARS-CoV-2聚合酶链反应检测阳性结果识别。
  • 共1176例,中位(IQR)年龄58(41-71)岁,630例(54%)为男性,中位(IQR)BMI 30(25-36),中位(IQR)序贯器官衰竭评估评分1(0-2)。
  • 样本包括16例美国印第安或阿拉斯加原住民、439例亚裔(未另行指定)、15例黑人、66例中国人、246例菲律宾人、76例西班牙裔、107例日本人、10例韩国人、299例夏威夷原住民、523例太平洋岛民(未另行指定)、156例萨摩亚人、5例越南人、311例白人(患者可识别为>1个种族或民族)。

研究设计与关键结果

  • 研究类型:回顾性队列研究;单家三级医疗中心;纳入2020年3月至2022年3月住院的1176例急性COVID-19患者;数据于2022年5月至2023年5月分析。
  • 暴露:需住院的COVID-19;主要结局与措施:电子病历数据,采用调整多因素logistic回归评估种族与民族、保险覆盖、接种至少1剂COVID-19疫苗、ICU转入、院内死亡及COVID-19变异株波次(pre-Delta vs Delta和Omicron)之间的关联。
  • 调整年龄、BMI、性别、合并症及社区社会经济状况后,保险类型与ICU转入无关(Medicare vs 商业保险:OR 0.84;95%CI 0.43-1.64),与院内死亡无关(Medicare vs 商业保险:OR 0.85;95%CI 0.36-2.03)。
  • 分解种族与民族显示菲律宾裔患者更可能院内死亡(OR 1.79;95%CI 1.04-3.03;P=.03)。
  • 按变异株波次分析,菲律宾裔患者死亡风险在pre-Delta时期最高(OR 2.72;95%CI 1.02-7.14;P=.04),日本裔患者死亡风险在pre-Delta时期最低(OR 0.19;95%CI 0.03-0.78;P=.04);夏威夷原住民患者死亡风险在Delta和Omicron时期最低(OR 0.35;95%CI 0.13-0.79;P=.02)。
  • Medicare保险患者较商业保险患者更可能接种至少1剂COVID-19疫苗(OR 1.85;95%CI 1.07-3.21;P=.03)。
  • 所有患者无论保险类型,接种至少1剂COVID-19疫苗者ICU转入降低(OR 0.40;95%CI 0.21-0.70;P=.002)、院内死亡降低(OR 0.42;95%CI 0.21-0.79;P=.01)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现说明疫苗接种仍是保护患者免于COVID-19死亡的关键工具;接种至少1剂COVID-19疫苗者ICU转入(OR 0.40;95%CI 0.21-0.70;P=.002)和院内死亡(OR 0.42;95%CI 0.21-0.79;P=.01)均降低。
  • 作者认为,分解种族与民族分析显示存在结局差异,提示可进一步研究这些差异的驱动因素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The people of Hawai'i have both high rates of health insurance and high levels of racial and ethnic diversity, but the degree to which insurance status and race and ethnicity contribute to health outcomes in COVID-19 remains unknown.

OBJECTIVE: To evaluate the associations of insurance coverage, race and ethnicity (using disaggregated race and ethnicity data), and vaccination with outcomes for COVID-19 hospitalization.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included hospitalized patients at a tertiary care medical center between March 2020 and March 2022. All patients hospitalized for acute COVID-19, identified based on diagnosis code or positive results on polymerase chain reaction-based assay for SARS-CoV-2, were included in analysis. Data were analyzed from May 2022 to May 2023.

EXPOSURE: COVID-19 requiring hospitalization.

MAIN OUTCOME AND MEASURES: Electronic medical record data were collected for all patients. Associations among race and ethnicity, insurance coverage, receipt of at least 1 COVID-19 vaccine, intensive care unit (ICU) transfer, in-hospital mortality, and COVID-19 variant wave (pre-Delta vs Delta and Omicron) were assessed using adjusted multivariable logistic regression.

RESULTS: A total of 1176 patients (median [IQR] age of 58 [41-71] years; 630 [54%] male) were hospitalized with COVID-19, with a median (IQR) body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of 30 (25-36) and Sequential Organ Failure Assessment score of 1 (0-2). The sample included 16 American Indian or Alaska Native patients, 439 Asian (not otherwise specified) patients, 15 Black patients, 66 Chinese patients, 246 Filipino patients, 76 Hispanic patients, 107 Japanese patients, 10 Korean patients, 299 Native Hawaiian patients, 523 Pacific Islander (not otherwise specified) patients, 156 Samoan patients, 5 Vietnamese patients, and 311 White patients (patients were able to identify as >1 race or ethnicity). When adjusting for age, BMI, sex, medical comorbidities, and socioeconomic neighborhood status, there were no differences in either ICU transfer (eg, Medicare vs commercial insurance: odds ratio [OR], 0.84; 95% CI, 0.43-1.64) or in-hospital mortality (eg, Medicare vs commercial insurance: OR, 0.85; 95% CI, 0.36-2.03) as a function of insurance type. Disaggregation of race and ethnicity revealed that Filipino patients were more likely to die in the hospital (OR, 1.79; 95% CI, 1.04-3.03; P = .03). When considering variant waves, mortality among Filipino patients was highest during the pre-Delta time period (OR, 2.72; 95% CI, 1.02-7.14; P = .04), when mortality among Japanese patients was lowest (OR, 0.19; 95% CI, 0.03-0.78; P = .04); mortality among Native Hawaiian patients was lowest during the Delta and Omicron period (OR, 0.35; 95% CI, 0.13-0.79; P = .02). Patients with Medicare, compared with those with commercial insurance, were more likely to have received at least 1 COVID-19 vaccine (OR, 1.85; 95% CI, 1.07-3.21; P = .03), but all patients, regardless of insurance type, who received at least 1 COVID-19 vaccine had reduced ICU admission (OR, 0.40; 95% CI, 0.21-0.70; P = .002) and in-hospital mortality (OR, 0.42; 95% CI, 0.21-0.79; P = .01).

CONCLUSIONS AND RELEVANCE: In this cohort study of hospitalized patients with COVID-19, those with government-funded insurance coverage (Medicare or Medicaid) had similar outcomes compared with patients with commercial insurance, regardless of race or ethnicity. Disaggregation of race and ethnicity analysis revealed substantial outcome disparities and suggests opportunities for further study of the drivers underlying such disparities. Additionally, these findings illustrate that vaccination remains a critical tool to protect patients from COVID-19 mortality.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Santi BM, Verhoef PA. COVID-19 Hospitalization in Hawai'i and Patterns of Insurance Coverage, Race and Ethnicity, and Vaccination. JAMA Netw Open. 2024. PMID: 38691362. doi:10.1001/jamanetworkopen.2024.3696

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。